Crinetics Pharmaceuticals Announces Resignation of COO Jeff Knight and Entry into Consulting Agreement

On April 10, 2026, Crinetics Pharmaceuticals, Inc. announced that Jeff Knight has resigned from his position as Chief Development and Operating Officer, effective the same day. Following his resignation, the Company entered into an Independent Consultant Agreement with Mr. Knight to provide expertise on operational and clinical development matters. The agreement runs from April 10, 2026, to April 10, 2027, with a potential six-month extension. Under the terms, Mr. Knight will be compensated at a rate of $400 per hour for up to 20 hours per month. While Mr. Knight's unvested restricted stock units and stock options were forfeited upon his resignation, his vested stock options will remain exercisable until three months after the conclusion of the consulting period. As part of the agreement, Mr. Knight provided a general release of claims against the Company. Crinetics will continue to provide certain indemnification rights and liability insurance coverage to Mr. Knight during the consulting term. The Company reported that this transition does not constitute "Good Reason" under his previous employment agreement.